Oligonucleotide-peptide conjugates have attracted considerable interest especially for biomedical uses. In the first part of this chapter, we describe protocols for the stepwise synthesis of oligonucleotides carrying peptide sequences at the 3'-end on a single support. The resulting oligonucleotide-peptide conjugates may be used as exogenous effectors for the specific control of gene expression. In the second part of this chapter, detailed postsynthetic conjugation protocols to introduce peptide sequences into oligonucleotide sequences are also presented.
Introduction
Oligonucleotide-peptide conjugates are chimeras of oligonucleotides and peptides that are produced in order to add some of the biological and/or biophysical properties of peptides to oligonucleotides. A peptide sequence may be attached to oligonucleotides either at the 5'-or 3'-terminal ends, or linked to the nucleobases at the internal positions (Fig. 1) . Most frequently, peptides are linked at the terminal positions of oligonucleotides since their attachment at internal sites can potentially interfere with the base-pairing properties of the nucleobases. Peptide-oligonucleotide conjugates are prepared through distinct conjugation chemistries, which include either stable or cleavable linkages. In the post-synthetic conjugation approach, the two moieties are prepared independently using solid-phase synthesis, and then thiols and maleimido groups are specifically introduced to link the two molecules together (1) . In the stepwise synthesis approach, oligonucleotide-peptide conjugates are prepared by the addition of protected amino acids and nucleotides during solid-phase synthesis on the same solid support (2) (3) (4) . In this case, the main challenge is to develop an effective protection strategy for peptide synthesis that is compatible with oligonucleotide synthesis. For example, during the final steps of solidphase peptide synthesis a treatment with acid is usually required, which can lead to partial depurination of DNA oligonucleotides. In the case of the synthesis of oligonucleotide 3'-peptide conjugates, the solution to this issue is the use of t-butoxycarbonyl (Boc)-protected amino acids carrying fluorenylmethyl (Fm) or fluorenylmethoxycarbonyl (Fmoc) groups for the protection of the side chains (2) (3) (4) . This unusual Boc/Fmoc strategy, described in several recent reviews (5) (6) (7) (8) (9) , is compatible with oligonucleotide synthesis, and most of the required amino acid derivatives can be obtained from commercial sources.
Herein, we describe protocols for the preparation of oligonucleotide-peptide conjugates developed in our research group at IRB. Specifically, we describe the stepwise synthesis of DNA and RNA molecules covalently linked to peptides that are designed to enhance cellular uptake in antisense (10) and RNA interference (11) (12) experiments. In addition, the synthesis of DNA molecules carrying peptide epitopes by post-synthetic conjugation (13) is also discussed. Glutamic and aspartic acid are protected with the Fm ester. Threonine, tyrosine and serine are protected with the acetyl group. Histidine can be protected with the tosyl group, and cysteine with the Fm or the tbutylthio group (7). The remaining amino acids were used without protection. Arginine can be protected with the di-Fmoc protecting group, but this derivative is not commercially available at present (see Note 1)
2. The coupling agent for peptide synthesis was benzotriazol-1-yl-oxy-tris(pyrrolidino)phosphonium hexafluorophosphate (PyBOP).
3. The solid-phase synthesis support, amino-polyethylene glycol-polystyrene (PEG-PS), was obtained from Perseptive Biosystems.
Synthesis of oligonucleotides carrying peptide sequences at the 3'-end
1. Oligonucleotide sequences were prepared by solid-phase synthesis using 2-cyanoethyl phosphoramidites as monomers. The phosphoramidites of the natural nucleosides are standard reagents that are commercially available (see Note 2). The base protection scheme employed during DNA synthesis was as follows: 2'-Deoxyguanosine was protected with either the isobutyryl group or the dimethylaminomethylidene group; and 2'-deoxycytidine and 2'-deoxyadenosine were protected with the benzoyl group. Base protection during RNA synthesis was as follows: Guanosine was protected with the dimethylaminomethylidene group; 4 cytidine was protected with the acetyl group; and adenosine with the benzoyl group. The 2'-OH protecting group employed for the RNA monomers was the t-butyldimethylsilyl (TBDMS) group. All of the preceding solutions can be obtained from the same companies that provide phosphoramidites (see
Note 2).
3. 6-Aminohexanol.
4. Succinic anhydride.
N,N-dimethylaminopyridine (DMAP).
6. 4-hydroxybutyric acid.
7. Preparative high-performance liquid chromatography (HPLC) system equipped with a Nucleosil® 120-10 C 18 column (250 x 4 mm) (Macherey-Nagel, Inc.).
8. Analytical HPLC system equipped with an XBridge TM OST C 18 column (2.5 µm, 4.6 x 50 mm) (Waters).
9. Solvent A for HPLC: 5% acetonitrile in 100 mM aqueous triethylammonium acetate (TEAA), pH 6.5.
10. Solvent B for HPLC: 70% acetonitrile in 100 mM aqueous TEAA, pH 6.5.
11. Voyager-DETMRP mass spectrometer equipped with a nitrogen laser (337 nm) (PerSeptive Biosystems).
12. Polyacrylamide gel electrophoresis system (Hoefer Scientific).
13. Stains-All nucleic acid and protein staining solution (Sigma-Aldrich) was prepared at 0.01% (w/v) in formamide /water (1/1.2 v/v).
Post-synthetic conjugation of peptides to oligonucleotides carrying thiol groups
1. The following reagents were used for the introduction of thiol groups into oligonucleotides and were obtained from commercial sources: At the 3'-end: 3'-thiol-modifier C3 S-S CPG; and at the 5'-end: 5'-thiol modifier C6 S-S phosphoramidite (see Note 2 and Fig. 2) . A 2'-deoxycytidine derivative was used for the introduction of a thiol group at internal nucleobase positions ( Fig. 2) , as described in ref. (13).
For the introduction of maleimido groups at the N-terminal position of peptides, 3-maleimidobenzoic acid
N-hydroxysuccinimide ester (MBS) was used.
3. Rink-Amide polystyrene solid support was used for the synthesis of peptides by the Fmoc / t-butyl strategy. 
Methods
There is currently great interest in the use of oligonucleotide-peptide conjugates for a variety of biomedical applications. As discussed in the introduction to this chapter, there are two major approaches that may be used to prepare these types of compounds (see Note 3). In the post-synthetic conjugation approach, the oligonucleotide and peptide components are built on separate supports using standard solid-phase protocols but are conveniently functionalized so that they may be linked together after synthesis. In the stepwise solid-phase approach, the oligonucleotide-peptide conjugate is prepared on a single support using special protecting groups in conjunction with modified synthesis protocols that minimize unwanted side-reactions. In this section, we describe specific protocols that our group has developed in recent years; several alternative protocols reported by others may also be found in the bibliography (5-9). As an example of the scope of the utility of the approaches described in this chapter, Table 1 lists several oligonucleotide-peptide conjugates that have been produced by our group using these protocols.
Prior to conducting any oligonucleotide-peptide synthesis work, firstly, a decision to employ either a stepwise or a post-synthetic conjugation protocol should be made. Post-synthetic conjugation protocols tend to offer a greater level of flexibility, as peptides can be introduced either at the 3' or 5'-ends of the oligonucleotides or at 6 internal nucleobases. Moreover, if the peptides are long and complex or if the oligonucleotides are long and highly modified, then post-synthetic conjugation protocols are generally more suitable. Unfortunately, not all types of peptides and oligonucleotides work well in these protocols. For example, these conjugation reactions are not very efficient when using hydrophobic peptides that are not very soluble in aqueous solvents. In addition, low yields have been observed during the conjugation of oligonucleotides to highly structured peptides with several positive charges. On the other hand, stepwise solid-phase protocols are efficient only when using short-length peptides and moderate-sized oligonucleotides. Furthermore, some amino acids such as arginine are difficult to introduce, as there is no good protecting group available for the guaninido group that can be removed with base (see Note 1). And finally, stepwise protocols are only efficient when synthesizing conjugates with the peptide linked at the 3'-end of the oligonucleotide (see Note 4). 
Preparation of Oligonucleotide-Peptide Conjugates by Stepwise Solid-Phase Synthesis
In the stepwise protocol presented below, oligonucleotide-peptide conjugates were synthesized on a polyethylene glycol-polystyrene (PEG-PS) support. This support was selected since it gave the best results for the coupling of amino acids and nucleoside phosphoramidites. Figure 3 outlines the general procedure for the stepwise synthesis of oligonucleotide-peptide conjugates on the same support. To avoid the use of strong acids in the presence of the oligonucleotide, the peptide component was synthesized first using the acid-labile Boc group to protect the α-amino function. The protecting groups for the side chains of the amino acids (Fmoc for Lys and Fm for Asp) and the linker for the first amino acid to the support were base-labile so that they could be removed at the same time as the protective groups for the nucleobases. To this end, 6-aminohexylsuccinyl was utilized as the linker molecule, yielding a peptide with an aminohexylamide group at the C-terminal. 
Solid-phase synthesis of the peptide moiety
1. Boc-6-aminohexyl hemisuccinate was synthesized as follows: Boc-aminohexanol (1 eq) was reacted with succinic anhydride (1.5 eq) and DMAP (1.5 eq) in DCM at room temperature overnight to form the corresponding hemisuccinate. The mixture was next dissolved with additional DCM and treated with a solution of 0.1 M NaH 2 PO 4 (pH 5). The organic layer was dried with anhydrous sodium sulphate and concentrated to dryness. The resulting compound was used in the next step without further purification. In order to deprotect conjugates containing DNA oligonucleotides,
Amino-polyethylene glycol-polystyrene solid (PEG-PS) support was washed with dichloromethane (DCM)
Step 3 below was next carried; for conjugates containing RNA oligonucleotides, Step 4 was carried out instead.
material was collected by centrifugation at 4500 × g for 5 min at 4 ºC, washed with ether and then centrifuged again. Finally, the collected residues were dissolved in water and the RNA-peptide conjugates were purified by HPLC as described in Step 5 below.
5. Reversed-phase HPLC purification of oligonucleotide-peptide conjugates was performed using a Nucleosil® 120-10 C 18 column (250 x 4 mm) under the following conditions for solvent A and solvent B:
20 min linear gradient from 15% to 80% solvent B, and 5 min 80% solvent B (DMT-on conditions); 20 min linear gradient from 0% to 50% B (DMT-off conditions); flow rate of 3 ml/min.
6. Characterization of oligonucleotide-peptide conjugates by mass spectrometry (MS) was performed as follows: MALDI-TOF MS spectra were acquired with a mass spectrometer equipped with a nitrogen laser at 337 nm using a 3-ns pulse. The matrix contained 2,4,6-trihydroxyacetophenone (THAP; 10 mg/ml in ACN / water, 1:1, v/v) and ammonium citrate (50 mg/ml in water) at a ratio of 9:1 (v/v). 
Introduction of guanidine groups
Oligodeoxynucleotide-peptide conjugates carrying lysine or ornithine residues can have these be converted to homoarginine or arginine by reaction with O-methylisourea as follows:
1. Oligodeoxynucleotide-peptide conjugates containing unprotected amines (~4.0 OD) were treated with a mixture (125 µl) prepared by combining 100 µL of a solution containing 1 g/mL O-methylisourea chloride in water with aqueous ammonia (32%, w/w; 125 µL).
2. After heating the above reaction mixture at 55 ºC overnight, the solvent was removed.
3. The resulting modified conjugates were desalted by Sephadex gel filtration, and further purified by preparative HPLC (see Subheading 3.2, Step 5). 
Preparation of Oligonucleotide-Peptides Conjugates by

Notes
1. The protection of arginine is difficult, as there is no good protecting group available for the guanidine group that can be removed in the presence of oligonucleotides. The use of a Di-Fmoc derivative of arginine has been reported by others (17) ; here, we describe a protocol for the guanidinylation of ornithine-peptides that yields arginine-peptides in excellent yields. This protocol can also be used for the synthesis of homoarginine peptides from lysine peptides. p18 +tiol t8
